American Journal of Cardiovascular Drugs

Acknowledgement
pp. 343-344(2)
Author: Adis International Limited

Angiotensin Antagonism in Patients with Heart Failure: ACE Inhibitors, Angiotensin Receptor Antagonists or Both?
pp. 345-353(9)
Authors: Nicholas L.M. Cruden; David E. Newby

Paclitaxel-Eluting Stents: Current Clinical Experience
pp. 355-360(6)
Authors: Eberhard Grube; Lutz Buellesfeld

Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists: Potential Contribution of Mechanisms Other Than AT1 Receptor Blockade
pp. 361-368(8)
Authors: Boris Schmidt; Helmut Drexler; Bernhard Schieffer

Reversal of Left Ventricular Hypertrophy: What Have Recent Trials Taught Us?
pp. 369-378(10)
Authors: Paolo Verdecchia; Fabio Angeli

Clinical and Experimental Experience with Factor Xa Inhibitors
pp. 379-384(6)
Authors: Juan F. Viles-Gonzalez; Juan Gaztanaga; Urooj M. Zafar; Valentin Fuster; Juan J. Badimon

Intravascular Brachytherapy: Indications and Management of Adverse Events
pp. 385-394(10)
Authors: Balram Bhargava; Ganesan Karthikeyan; Prabhakar Tripuraneni

Valsartan: A Review of its Use in Patients with Heart Failure and/or Left Ventricular Systolic Dysfunction After Myocardial Infarction
pp. 395-404(10)
Authors: Katherine F. Croom; Gillian M. Keating

Ezetimibe/Simvastatin: A Review of its Use in the Management of Hypercholesterolemia
pp. 405-422(18)
Authors: David Murdoch; Lesley J. Scott

Cardiac Syndrome X: Diagnosis, Pathogenesis and Management
pp. 423-423(1)
Author: Adis International Limited

The Author’s Reply
pp. 423-423(1)
Author: Adis International Limited